Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference.

The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1.

The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Contacts

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com



Media:

Email: media@evolus.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  197.93
-1.67 (-0.84%)
AAPL  259.15
-2.58 (-0.99%)
AMD  206.61
+0.67 (0.33%)
BAC  52.08
-0.44 (-0.84%)
GOOG  306.92
-2.45 (-0.79%)
META  642.53
-7.28 (-1.12%)
MSFT  402.31
+0.47 (0.12%)
NVDA  182.52
-4.42 (-2.36%)
ORCL  157.59
+1.11 (0.71%)
TSLA  412.90
-4.17 (-1.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.